Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01791686 · ClinicalTrials.gov registry record · Phase 1
Clinical Trial of CDX-1135 in Pediatric and Adult Patients With Dense Deposit Disease
A Phase 1 study, sponsored by Celldex Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT01791686 is a Phase 1 study that was terminated before completion, run by Celldex Therapeutics. The registered enrollment target is 1 participants.
The verdict
NCT01791686, a Phase 1 study, was terminated before completion, sponsored by Celldex Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
This study is evaluating the study drug (CDX-1135) in patients with dense deposit disease (DDD). The objective is to evaluate the safety and activity of repeated doses of CDX-1135 in pediatric and adult patients with DDD. After screening, eligible patients will be entered into the Induction Period. The Induction Period is up to 4 weeks. Following normalization of complement activity, patients will enter into the Maintenance Period.The total treatment duration is up to 26 weeks.
Interventions
- DRUG CDX-1135
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2013-01 |
| Est. Completion | 2014-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01791686
The ClinicalTrials.gov registry entry for NCT01791686 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celldex Therapeutics, which has 42 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CDX-1135 is the first listed.
NCT01791686 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01791686 about?
NCT01791686 is a clinical study titled "Clinical Trial of CDX-1135 in Pediatric and Adult Patients With Dense Deposit Disease". This study is evaluating the study drug (CDX-1135) in patients with dense deposit disease (DDD). The objective is to evaluate the safety and activity of repeated doses of CDX-1135 in pediatric and adult patients with DDD. After screening, eligible patients will be entered into the Induction Period. ...
What is the current status of trial NCT01791686?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2013-01. Estimated completion is 2014-03.
What interventions are being tested in trial NCT01791686?
The interventions under investigation include: CDX-1135 (DRUG).
Who is sponsoring clinical trial NCT01791686?
This trial is sponsored by Celldex Therapeutics, which has 42 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.